A team led by Massachusetts General Hospital (MGH) investigators has confirmed that the imaging agent Pittsburgh Compound B (PiB) binds to the protein in amyloid plaques that characterize Alzheimer’s disease in the human brain. Their report in the March Archives of Neurology describes the first postmortem neuropathological study of a dementia patient who had previously participated in a PET imaging study using PiB. >>> Discuss This Story
